Loading clinical trials...

COMPLETEDNA

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Monocytic Leukemia

NCT05739409•Institute of Hematology & Blood Diseases Hospital, China

Summary

This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.

Detailed Description

This study will recruit LILRB4-positive monocytic leukemia subjects who will receive cyclophosphamide and fludarabine on days -5 to -3 prior to cell infusion, followed by LILRB4 STAR-T cells. The primary objective of the study was to evaluate the safety and tolerability of LILRB4 STAR-T cells in subjects with monocytic leukemia. The secondary objective was to evaluate the therapeutic efficacy, pharmacodynamics and pharmacokinetics of LILRB4 STAR-T cells.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\-
•1\. Aged 18-70 years, gender is not limited 2. Acute myelogenous leukemia or chronic monocytic leukemia:
•1. Subjects diagnosed with acute myelogenous leukemia according to WHO 2016 criteria and according to the "Chinese Guidelines for the Diagnosis and Treatment of Relapsed and Refractory Acute Myeloid Leukemia (2021 Edition)" should meet any of the following relapsed and refractory (R/R) acute myelogenous leukemia patients:
•1. Patients who have failed two cycles of standard chemotherapy;
•2. No remission was achieved after 1 cycle of the standard regimen and could not continue with the standard regimen due to age, comorbidities, physical status, and / or adverse risk factors;
•3. Relapse within 12 months after consolidation and intensification therapy after complete remission (CR);
•4. Relapse after 12 months but failed to respond to conventional treatment;
•5. two or more recurrences;
•6. persistent extramedullary leukemia;
•7. For age\> 60 years: standard regimen chemotherapy due to age, comorbidities, physical status, and / or adverse risk factors, and treated with 4 cycles of demethylating drugs (such as decitabine and / or azacitidine) or 2 cycles of low-dose chemotherapy ± demethylating drugs。 Note: Definition of relapse: reoccurrence of leukemic cells in peripheral blood after CR or in bone marrow\> 5% (except for other causes such as marrow regeneration after consolidation chemotherapy) or extramedullary infiltration of leukemic cells.
+5 more criteria

Exclusion Criteria

•1. Patients who have used chimeric antigen receptor T-cell immunotherapy therapy or any other gene transduction product within 3 months of signing the informed consent, except without detectable chimeric antigen receptor T-cell ratio or chimeric antigen receptor T-cell ratio below the lower test limit; or patients who have participated in other interventional clinical studies within 4 weeks prior to signing the informed consent；
•2. Any of the following cardiovascular and cerebrovascular diseases occurred within 6 months before screening:
•1. congestive heart failure(NYHA stage III),myocardial infarction,unstable angina pectoris,congenital long QT syndrome,Anterior left block,coronary angioplasty,stent implantation,Coronary/peripheral artery bypass grafting,cerebrovascular accident,Transient ischemic attack or pulmonary embolism,Asymptomatic right bundle branch block was allowed;
•2. Serious arrhythmias requiring treatment (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes, etc.);
•3. uncontrolled hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg), a history of hypertensive crisis or hypertensive encephalopathy;
•3. Subjects with positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core antibody (HBcAb) and hepatitis B virus DNA copy number above the detection limit; subjects with positive hepatitis C virus (HCV) antibody and positive HCV RNA copy number above the detection limit; positive pallidum antibody test；
•4. Patients with known systemic lupus erythematosus, combined active or uncontrolled autoimmune diseases (such as Crohns disease, rheumatoid arthritis, autoimmune hemolytic anemia, etc.), primary or secondary immune deficiency (such as HIV infection or severe infectious diseases, etc.)；
•5. Previous or concurrent other incurable malignancies with unstable control,Affect the long-term survival of subjects, except for cured cervical carcinoma in situ, non-invasive basal cell or squamous cell skin cancer or other local prostate cancer after radical treatment, ductal carcinoma in situ after radical resection and at least 5 Years without recurrence of malignant tumor;
•6. Patients with current disease or a previous history of central nervous system disease, such as seizures, stroke, severe brain injury, aphasia, paralysis, dementia, Parkinson's disease, mental illness, etc；
•7. Patients living with an active central nervous system leukemia (CNSL)；
+9 more criteria

Locations (2)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

Institute of Hematology & Blood Diseases Hospital

Tianjin, China

Key Dates

Start Date

February 16, 2023

Primary Completion Date

May 9, 2023

Completion Date

May 9, 2023

Last Updated

February 11, 2026

Enrollment

ACTUAL participants

Conditions

Acute Myelogenous LeukemiaChronic Myelomonocytic Leukemia

Interventions

LILRB4 STAR-T cells injection

BIOLOGICAL

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

View study

RECRUITINGPHASE1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Inclusion Criteria

Exclusion Criteria

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer